↓ Skip to main content

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, March 2012
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer
Published in
Journal of Experimental & Clinical Cancer Research, March 2012
DOI 10.1186/1756-9966-31-26
Pubmed ID
Authors

Farbod Shojaei, Nathan Scott, Xiaolin Kang, Patrick B Lappin, Amanda A Fitzgerald, Shannon Karlicek, Brett H Simmons, Aidong Wu, Joseph H Lee, Simon Bergqvist, Eugenia Kraynov

Abstract

Osteopontin (OPN), also known as SPP1 (secreted phosphoprotein), is an integrin binding glyco-phosphoprotein produced by a variety of tissues. In cancer patients expression of OPN has been associated with poor prognosis in several tumor types including breast, lung, and colorectal cancers. Despite wide expression in tumor cells and stroma, there is limited evidence supporting role of OPN in tumor progression and metastasis. Using phage display technology we identified a high affinity anti-OPN monoclonal antibody (hereafter AOM1). The binding site for AOM1 was identified as SVVYGLRSKS sequence which is immediately adjacent to the RGD motif and also spans the thrombin cleavage site of the human OPN. AOM1 efficiently inhibited OPNa binding to recombinant integrin αvβ3 with an IC50 of 65 nM. Due to its unique binding site, AOM1 is capable of inhibiting OPN cleavage by thrombin which has been shown to produce an OPN fragment that is biologically more active than the full length OPN. Screening of human cell lines identified tumor cells with increased expression of OPN receptors (αvβ3 and CD44v6) such as mesothelioma, hepatocellular carcinoma, breast, and non-small cell lung adenocarcinoma (NSCLC). CD44v6 and αvβ3 were also found to be highly enriched in the monocyte, but not lymphocyte, subset of human peripheral blood mononuclear cells (hPBMCs). In vitro, OPNa induced migration of both tumor and hPBMCs in a transwell migration assay. AOM1 significantly blocked cell migration further validating its specificity for the ligand. OPN was found to be enriched in mouse plasma in a number of pre-clinical tumor model of non-small cell lung cancers. To assess the role of OPN in tumor growth and metastasis and to evaluate a potential therapeutic indication for AOM1, we employed a Kras(G12D-LSL)p53(fl/fl) subcutaneously implanted in vivo model of NSCLC which possesses a high capacity to metastasize into the lung. Our data indicated that treatment of tumor bearing mice with AOM1 as a single agent or in combination with Carboplatin significantly inhibited growth of large metastatic tumors in the lung further supporting a role for OPN in tumor metastasis and progression.

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Portugal 1 2%
Germany 1 2%
Unknown 38 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 24%
Student > Bachelor 7 17%
Researcher 6 15%
Student > Master 5 12%
Student > Doctoral Student 2 5%
Other 4 10%
Unknown 7 17%
Readers by discipline Count As %
Medicine and Dentistry 13 32%
Biochemistry, Genetics and Molecular Biology 8 20%
Agricultural and Biological Sciences 7 17%
Immunology and Microbiology 3 7%
Chemical Engineering 1 2%
Other 2 5%
Unknown 7 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2022.
All research outputs
#7,202,029
of 22,096,435 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#388
of 1,972 outputs
Outputs of similar age
#109,233
of 290,039 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#1
of 1 outputs
Altmetric has tracked 22,096,435 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,972 research outputs from this source. They receive a mean Attention Score of 3.7. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,039 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them